The compound 10058‐F4 was found to be c‐Myc inhibitor against HL60 cells with an IC50 value of 49.0 μM, while the compound 28RH‐NCN‐1 demonstrated more potential in inhibiting the binding of c‐Myc/Max to E‐box motifs on the same cells.19, 20 Further, the compound MYCi361 inhibits MYC‐dependent cancer cell proliferation and tumorigenicity, for example, it showed potency against MycCaP cell with an IC50 value of 2.9 μM.13 Considering these structural features, we designed a series of c‐Myc inhibitors by integrating both 3,5‐bis(trifluoromethyl)benzene and thioxothiazolidinone ring. This evidence concerns the gene MYC and cancer.